ACAD
ACADIA Pharmaceuticals
No price yet
Announcements
Nothing here yet
Daily updates
- ACADIA to Present Full Phase 2 RADIANT Results for Remlifanserin at CTAD in November 2026Oct 18, 2026
- Acadia reported topline Phase 2 RADIANT results for remlifanserin in Alzheimer’s disease psychosis, with the 60 mg cohort narrowly missing statistical significance on the SAPS-H+D primary endpoint.Sep 25, 2026
- Acadia reported topline Phase 2 RADIANT results for remlifanserin in Alzheimer's disease psychosis, with the 60 mg cohort narrowly missing statistical significance on the SAPS-H+D primary endpoint while showing nominal CGI-S-ADP improvements and favorable overall safety.Sep 24, 2026
- Remlifanserin is being evaluated in the Phase 2 RADIANT trial for Alzheimer's disease psychosis, with topline data expected in September or October 2026 under FDA Fast Track designation.Sep 19, 2026
FDA designations
Nothing here yet
News
- Acadia Pharmaceuticals reports Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin for Alzheimer’s disease psychosisSep 24, 2026
- The European Commission approved DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the EUAug 24, 2026
- Acadia Pharmaceuticals receives FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosisJul 21, 2026
- DAYBUE is now widely available in the U.S. for treating Rett syndromeApr 7, 2026
- Acadia Pharmaceuticals announces FDA approval of DAYBUE® STIX powder formulation for Rett syndromeDec 12, 2025